162 related articles for article (PubMed ID: 23749918)
1. Weekly paclitaxel--an effective treatment for advanced breast cancer.
Kellokumpu-Lehtinen P; Tuunanen T; Asola R; Elomaa L; Heikkinen M; Kokko R; Järvenpää R; Lehtinen I; Maiche A; Kaleva-Kerola J; Huusko M; Möykkynen K; Ala-Luhtala T
Anticancer Res; 2013 Jun; 33(6):2623-7. PubMed ID: 23749918
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
Kim R; Osaki A; Toge T
Oncol Rep; 2003; 10(1):145-50. PubMed ID: 12469161
[TBL] [Abstract][Full Text] [Related]
6. [Weekly paclitaxel therapy for metastatic breast cancer].
Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
[TBL] [Abstract][Full Text] [Related]
7. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
Akerley W; Sikov WM; Cummings F; Safran H; Strenger R; Marchant D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-87-S17-90. PubMed ID: 9374102
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of weekly paclitaxel administration for metastatic breast cancer based on time to progression (TTP) and survival].
Emoto T; Yoshikawa K; Yoshioka Y; Nezu R; Fujikawa M; Fujii M; Maeda S; Naka Y; Komaki T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):817-22. PubMed ID: 12852349
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
[TBL] [Abstract][Full Text] [Related]
12. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital.
Lu CH; Lin YC; Chang HK
Chang Gung Med J; 2007; 30(1):33-40. PubMed ID: 17477027
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
Klaassen U; Harstrick A; Wilke H; Seeber S
Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
18. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Yonemori K; Katsumata N; Uno H; Matsumoto K; Kouno T; Tokunaga S; Yamanaka Y; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2005 Feb; 89(3):237-41. PubMed ID: 15754121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
